Unnatural Dipeptide Synthesis with Bioactivity Against P. aeruginosa
| dc.contributor.advisor | Mudrack, Kristen | |
| dc.contributor.author | Geren, Kellee | |
| dc.contributor.author | Lamb, Andi | |
| dc.date.accessioned | 2019-04-24T12:31:42Z | |
| dc.date.available | 2019-04-24T12:31:42Z | |
| dc.date.issued | 2019-04 | |
| dc.description.abstract | Pseudomonas aeruginosa is a gram-negative bacterium that is difficult to treat. Cystic Fibrosis patients are likely to be affected by Pseudomonas aeruginosa, forcing patients to be prescribed antibiotics for an extended period of time. Antibiotic resistance develops quickly for antibiotics due to overuse and overexposure, therefore, new treatments that are effective and inexpensive to create are needed. In collaboration with the distributed drug discovery (D3) program started by IUPUI, solid phase synthesis of unnatural dipeptides was utilized to make six small molecule antibiotics that have potential bioactivity against P. aeruginosa. A microbiology assay was used to determine the interaction of the dipeptides with P. aeruginosa. The six novel dipeptides were tested against current antibiotic therapies to determine their effectiveness. | en_US |
| dc.identifier.uri | http://hdl.handle.net/11558/4269 | |
| dc.language.iso | en_US | en_US |
| dc.subject | Pseudomonas aeruginosa | en_US |
| dc.subject | Dipeptides | en_US |
| dc.subject | Antibiotics | en_US |
| dc.subject | Cystic Fibrosis | en_US |
| dc.subject | RISE Above Research Conference | |
| dc.title | Unnatural Dipeptide Synthesis with Bioactivity Against P. aeruginosa | en_US |
| dc.type | Working Paper | en_US |